Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

miRNAs Signatures In Patients With Acute Liver Injury: Clinical Concerns and Correlations

Author(s): Hitarthi S. Vyas, Kapil K. Upadhyay and Ranjitsinh V. Devkar*

Volume 20, Issue 5, 2020

Page: [325 - 335] Pages: 11

DOI: 10.2174/1566524020666191211153546

Price: $65

Abstract

Non-coding RNAs can be highly exploited for their biological significance in living systems. miRNAs are in the upstream position of cellular regulation cascade and hold merit in its state. A plethora of information is available on a wide variety of miRNAs that undergo alterations in experimentally induced models of liver injuries. The underlying mechanisms governed by these miRNAs have been inferred through cellbased experiments but the scientific knowledge on miRNA signatures in patients with liver injury are primordial and lack scientific clarity. Hence, it is crucial to get insight into the status and synergy of miRNAs in patients, with varying degrees of acute toxic manifestations in the liver. Though some miRNAs are being investigated in clinical trials, a major research lacuna exists with regard to the functional role of other miRNAs in liver diseases. This review article is a meticulous compilation of disease based or drug/alcohol based acute liver injuries in patients and resultant alteration in their miRNA profile. Investigative reports on underlying miRNA-liver crosstalk in cell-based or murine models are also discussed herein to draw a correlation with clinical findings.

Keywords: microRNAs, acute liver injury, patients, biomarker, cirrhosis, murine models.

Next »
[1]
Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12(1): 145.
[http://dx.doi.org/10.1186/s12916-014-0145-y] [PMID: 25242656]
[2]
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019; 70: 151-71.
[PMID: 30266282]
[3]
Uhl P, Fricker G, Haberkorn U, Mier W. Current status in the therapy of liver diseases. Int J Mol Sci 2014; 15(5): 7500-12.
[http://dx.doi.org/10.3390/ijms15057500] [PMID: 24786290]
[4]
Huang Y, Yan Y, Xv W, Qian G, Li C, Zou H, et al. A new insight into the roles of MiRNAs in metabolic syndrome. BioMed research international 2018 2018.
[http://dx.doi.org/10.1155/2018/7372636]
[5]
Vafadar A, Shabaninejad Z, Movahedpour A, et al. Long non-coding RNAs as epigenetic regulators in cancer. Curr Pharm Des 2019; 25(33): 3563-77.
[http://dx.doi.org/10.2174/1381612825666190830161528] [PMID: 31470781]
[6]
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12(12): 861-74.
[http://dx.doi.org/10.1038/nrg3074] [PMID: 22094949]
[7]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 2018; 9: 402.
[http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]
[8]
Nishikawa T, Bellance N, Damm A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J Hepatol 2014; 60(6): 1203-11.
[http://dx.doi.org/10.1016/j.jhep.2014.02.014] [PMID: 24583248]
[9]
Tétreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin Biochem 2013; 46(10-11): 842-5.
[http://dx.doi.org/10.1016/j.clinbiochem.2013.02.009] [PMID: 23454500]
[10]
Zhou X, Duan X, Qian J, Li F. Abundant conserved microRNA target sites in the 5′-untranslated region and coding sequence. Genetica 2009; 137(2): 159-64.
[http://dx.doi.org/10.1007/s10709-009-9378-7] [PMID: 19578934]
[11]
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem 2011; 67(1): 129-39.
[http://dx.doi.org/10.1007/s13105-010-0050-6] [PMID: 20981514]
[12]
Chen Y, Verfaillie CM. MicroRNAs: the fine modulators of liver development and function. Liver Int 2014; 34(7): 976-90.
[http://dx.doi.org/10.1111/liv.12496] [PMID: 24517588]
[13]
Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol 2009; 15(45): 5633-40.
[http://dx.doi.org/10.3748/wjg.15.5633] [PMID: 19960558]
[14]
Organization WH. Global hepatitis report 2017. World Health Organization 2017.
[15]
Bihrer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011; 6(10) e26971
[http://dx.doi.org/10.1371/journal.pone.0026971] [PMID: 22066022]
[16]
Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013; 58(3): 863-71.
[http://dx.doi.org/10.1002/hep.26296] [PMID: 23390075]
[17]
Wang JH, Jiang D, Rao HY, Zhao JM, Wang Y, Wei L. Absolute quantification of serum microRNA-122 and its correlation with liver inflammation grade and serum alanine aminotransferase in chronic hepatitis C patients. Int J Infect Dis 2015; 30: 52-6.
[http://dx.doi.org/10.1016/j.ijid.2014.09.020] [PMID: 25461662]
[18]
Morita K, Taketomi A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011; 31(4): 474-84.
[http://dx.doi.org/10.1111/j.1478-3231.2010.02433.x] [PMID: 21199296]
[19]
Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM. Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol 2014; 86(9): 1507-14.
[http://dx.doi.org/10.1002/jmv.23987] [PMID: 24895202]
[20]
Diaz G, Melis M, Tice A, et al. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer 2013; 133(4): 816-24.
[http://dx.doi.org/10.1002/ijc.28075] [PMID: 23390000]
[21]
Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47(4): 1223-32.
[http://dx.doi.org/10.1002/hep.22158] [PMID: 18307259]
[22]
Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56(5): 1631-40.
[http://dx.doi.org/10.1002/hep.25849] [PMID: 22610915]
[23]
Banaudha K, Kaliszewski M, Korolnek T, et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011; 53(1): 53-61.
[http://dx.doi.org/10.1002/hep.24016] [PMID: 20967756]
[24]
Bandiera S, Pernot S, El Saghire H, et al. Hepatitis C virus-induced upregulation of microRNA miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J Virol 2016; 90(14): 6387-400.
[http://dx.doi.org/10.1128/JVI.00619-16] [PMID: 27147737]
[25]
Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29(36): 4781-8.
[http://dx.doi.org/10.1200/JCO.2011.38.2697] [PMID: 22105822]
[26]
Zheng Q-F, Zhang J-Y, Wu J-S, et al. Upregulation of miRNA-130a represents good prognosis in patients With HBV-related acute-on-chronic liver failure: A prospective study. Medicine (Baltimore) 2016; 95(6) e2639
[http://dx.doi.org/10.1097/MD.0000000000002639] [PMID: 26871786]
[27]
Ji F, Yang B, Peng X, Ding H, You H, Tien P. Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 2011; 18(7): e242-51.
[http://dx.doi.org/10.1111/j.1365-2893.2011.01443.x] [PMID: 21692939]
[28]
Zhang H, Li Q-Y, Guo Z-Z, et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012; 18(37): 5188-96.
[PMID: 23066312]
[29]
Yamaura Y, Tatsumi N, Takagi S, et al. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin Biochem 2017; 50(18): 1034-9.
[http://dx.doi.org/10.1016/j.clinbiochem.2017.08.010] [PMID: 28823616]
[30]
Tan Y, Ge G, Pan T, Wen D, Gan J. Serum MiRNA panel as potential biomarkers for chronic hepatitis B with persistently normal alanine aminotransferase. Clin Chim Acta 2015; 451(Pt B): 232-9.
[http://dx.doi.org/10.1016/j.cca.2015.10.002] [PMID: 26483130]
[31]
Ding W, Xin J, Jiang L, et al. Characterisation of peripheral blood mononuclear cell microRNA in hepatitis B-related acute-on-chronic liver failure. Sci Rep 2015; 5: 13098.
[http://dx.doi.org/10.1038/srep13098] [PMID: 26267843]
[32]
Ura S, Honda M, Yamashita T, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49(4): 1098-112.
[http://dx.doi.org/10.1002/hep.22749] [PMID: 19173277]
[33]
Arataki K, Hayes CN, Akamatsu S, et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013; 85(5): 789-98.
[http://dx.doi.org/10.1002/jmv.23540] [PMID: 23508904]
[34]
Waidmann O, Bihrer V, Pleli T, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19(2): e58-65.
[http://dx.doi.org/10.1111/j.1365-2893.2011.01536.x] [PMID: 22239527]
[35]
Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 2012; 55(3): 730-41.
[http://dx.doi.org/10.1002/hep.24809] [PMID: 22105316]
[36]
Sarkar N, Panigrahi R, Pal A, et al. Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes. J Viral Hepat 2015; 22(10): 817-27.
[http://dx.doi.org/10.1111/jvh.12390] [PMID: 25720442]
[37]
Lan SH, Wu SY, Zuchini R, et al. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 2014; 59(2): 505-17.
[http://dx.doi.org/10.1002/hep.26659] [PMID: 23913306]
[38]
Guo H, Liu H, Mitchelson K, et al. MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology 2011; 54(3): 808-19.
[http://dx.doi.org/10.1002/hep.24441] [PMID: 21608007]
[39]
Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52(1): 60-70.
[http://dx.doi.org/10.1002/hep.23660] [PMID: 20578129]
[40]
Mirzaei HR, Sahebkar A, Mohammadi M, et al. Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des 2016; 22(34): 5257-69.
[http://dx.doi.org/10.2174/1381612822666160303110838] [PMID: 26935703]
[41]
Weiler-Normann C, Lohse AW. Acute autoimmune hepatitis: many open questions. J Hepatol 2014; 61(4): 727-9.
[http://dx.doi.org/10.1016/j.jhep.2014.06.030] [PMID: 24999018]
[42]
Migita K, Komori A, Kozuru H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One 2015; 10(11) e0136908
[http://dx.doi.org/10.1371/journal.pone.0136908] [PMID: 26575387]
[43]
Blaya D, Aguilar-Bravo B, Hao F, et al. Expression of microRNA-155 in inflammatory cells modulates liver injury. Hepatology 2018; 68(2): 691-706.
[http://dx.doi.org/10.1002/hep.29833] [PMID: 29420849]
[44]
Song L, Zhang Z, Zhang J, et al. Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice. Exp Ther Med 2016; 12(2): 889-94.
[http://dx.doi.org/10.3892/etm.2016.3375] [PMID: 27446292]
[45]
Bae JS, Kim J-H, Pasaje CFA, et al. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis 2012; 44(10): 849-54.
[http://dx.doi.org/10.1016/j.dld.2012.04.021] [PMID: 22658643]
[46]
Cheong JY, Shin HD, Kim YJ, Cho SW. Association of polymorphism in MicroRNA 219-1 with clearance of hepatitis B virus infection. J Med Virol 2013; 85(5): 808-14.
[http://dx.doi.org/10.1002/jmv.23551] [PMID: 23508906]
[47]
Wang H, Yu B, Deng J, Jin Y, Xie L. Serum miR-122 correlates with short-term mortality in sepsis patients. Crit Care 2014; 18(6): 704.
[http://dx.doi.org/10.1186/s13054-014-0704-9] [PMID: 25672224]
[48]
Upadhyay KK, Jadeja RN, Thadani JM, et al. Carbon monoxide releasing molecule A-1 attenuates acetaminophen-mediated hepatotoxicity and improves survival of mice by induction of Nrf2 and related genes. Toxicol Appl Pharmacol 2018; 360: 99-108.
[http://dx.doi.org/10.1016/j.taap.2018.09.034] [PMID: 30273691]
[49]
Yang X, Salminen WF, Shi Q, et al. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol Appl Pharmacol 2015; 284(2): 180-7.
[http://dx.doi.org/10.1016/j.taap.2015.02.013] [PMID: 25708609]
[50]
Yu D, Wu L, Gill P, et al. Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol 2018; 92(2): 845-58.
[http://dx.doi.org/10.1007/s00204-017-2090-y] [PMID: 29067470]
[51]
Gill P, Bhattacharyya S, McCullough S, et al. MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity. Sci Rep 2017; 7(1): 12331.
[http://dx.doi.org/10.1038/s41598-017-11811-y] [PMID: 28951593]
[52]
Vliegenthart AD, Shaffer JM, Clarke JI, et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep 2015; 5: 15501.
[http://dx.doi.org/10.1038/srep15501] [PMID: 26489516]
[53]
Vliegenthart ADB, Berends C, Potter CMJ, Kersaudy-Kerhoas M, Dear JW. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol 2017; 83(9): 2027-33.
[http://dx.doi.org/10.1111/bcp.13282] [PMID: 28257154]
[54]
Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA 2014; 111(33): 12169-74.
[http://dx.doi.org/10.1073/pnas.1412608111] [PMID: 25092309]
[55]
Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54(5): 1767-76.
[http://dx.doi.org/10.1002/hep.24538] [PMID: 22045675]
[56]
Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int 2014; 34(3): 367-78.
[http://dx.doi.org/10.1111/liv.12322] [PMID: 24118944]
[57]
Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. Laboratory animals 2015; 491_suppl:: 4-11.
[http://dx.doi.org/10.1177/0023677215571192]
[58]
Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53(1): 209-18.
[http://dx.doi.org/10.1002/hep.23922] [PMID: 20890893]
[59]
Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int 2017; 37(5): 757-64.
[http://dx.doi.org/10.1111/liv.13312] [PMID: 27860186]
[60]
López-Riera M, Conde I, Tolosa L, et al. New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease. Front Pharmacol 2017; 8: 3.
[http://dx.doi.org/10.3389/fphar.2017.00003] [PMID: 28179883]
[61]
Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut 2016; 65(9): 1535-45.
[http://dx.doi.org/10.1136/gutjnl-2015-311314] [PMID: 27196584]
[62]
Satishchandran A, Ambade A, Rao S, et al. MicroRNA 122, regulated by GRLH2, protects livers of mice and patients from ethanol-induced liver disease. Gastroenterology 2018; 154(1): 238-52. e7
[63]
Li M, He Y, Zhou Z, et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils. Gut 2017; 66(4): 705-15.
[http://dx.doi.org/10.1136/gutjnl-2016-311861] [PMID: 27679493]
[64]
Wan Y, McDaniel K, Wu N, et al. Regulation of cellular senescence by miR-34a in alcoholic liver injury. Am J Pathol 2017; 187(12): 2788-98.
[http://dx.doi.org/10.1016/j.ajpath.2017.08.027] [PMID: 29128099]
[65]
Tang Y, Banan A, Forsyth CB, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008; 32(2): 355-64.
[http://dx.doi.org/10.1111/j.1530-0277.2007.00584.x] [PMID: 18162065]
[66]
McDaniel K, Huang L, Sato K, et al. The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. J Biol Chem 2017; 292(27): 11336-47.
[http://dx.doi.org/10.1074/jbc.M116.773291] [PMID: 28536261]
[67]
Eguchi A, Lazaro RG, Wang J, et al. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology 2017; 65(2): 475-90.
[http://dx.doi.org/10.1002/hep.28838] [PMID: 27639178]

Rights & Permissions Print Cite
Article Metrics
7
2
© 2024 Bentham Science Publishers | Privacy Policy